Press Release Archive

October 22, 2013 - Pfizer Inc. Continues Development Program For Remoxy® (oxycodone) Extended-Release Capsules CII

Pfizer Inc. (NYSE: PFE) announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII.  Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June 2011. 

October 18, 2013 - Pfizer Reports Top-Line Results From Two Lyrica® Capsules CV Phase 3b Studies

Pfizer Inc. (NYSE: PFE) announced today top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.  The fibromyalgia study, A0081275 met its primary endpoint, showing a reduction in pain associated with fibromyalgia in patients who were treated concurrently with antidepressant therapy for comorbid depression.  Separately, the painful DPN study, A0081269 did not meet its co-primary endpoints by sufficiently reducing DPN pain and DPN pain on walking compared to placebo.

October 17, 2013 - Pfizer Receives European Approval For Label Update Regarding The Use Of Prevenar 13 In Certain High-Risk Populations

Pfizer Inc. (NYSE: PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company’s pneumococcal conjugate vaccine Prevenar 13[*] (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.  The updated label now includes information describing the use of the vaccine in preterm infants, children and adolescents with sickle cell disease who were previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine, and adults with human immunodeficiency virus (HIV) infection who were previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine.

October 16, 2013 - Grantmakers In Aging receives $1.3 million grant renewal from the Pfizer Foundation to help communities become more “age-friendly”

Grantmakers In Aging (GIA), a national association of funders, and the Pfizer Foundation today announced a second year of funding totaling $1.3 million for Community AGEnda, an initiative aimed at helping American communities become more age-friendly, meaning great places to grow up and grow old. The award will support grants up to $140,000 from GIA to each of the five participating Community AGEnda communities, in Arizona, Florida, Georgia, Indiana, and greater Kansas City. Funding for Community AGEnda is provided to GIA by the Pfizer Foundation.

October 9, 2013 - ChapStick® Announces Olympic Gold Medalist Alex Morgan As New Face Of The Brand

Pfizer® Consumer Healthcare, the makers of ChapStick®, America’s favorite lip balm, today announced Alex Morgan, Olympic gold medalist and member of the U.S. Women’s National Soccer Team, as the brand’s newest spokesperson.  Morgan, a long-time ChapStick loyalist, will serve as the first brand spokesperson in more than a decade and will appear in national television and print advertising, set to debut November 4, elevating the importance of lip health and fostering continued innovation for the iconic and beloved brand.

October 9, 2013 - Pfizer Announces Top-Line Results Of The First Two Of Five Phase 3 Clinical Trials Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

Pfizer Inc. (NYSE:PFE) announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).  These are the first two of five studies

October 3, 2013 - Pfizer Inc. Announces FDA Approval Of DUAVEETM (conjugated estrogens/ bazedoxifene) For The Treatment Of Moderate-To-Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause And The Prevention Of Postmenopausal Osteoporosis [1]

Pfizer Inc. (NYSE: PFE), a leader in the development of treatments for menopausal symptoms, is pleased to announce that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis [1].  When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk and non-estrogen medication should be carefully considered [1].  DUAVEE is a once daily tablet taken orally. 

October 2, 2013 - International Atherosclerosis Society And Pfizer Independent Grants For Learning & Change Collaborate On New Grant Opportunity

NEW YORK, N.Y., October 2 - Today the International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) announce their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.

October 1, 2013 - Pfizer Invites Public To View And Listen To Webcast Of October 29 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2013.  The purpose of the call is to provide an update

September 30, 2013 - Shantanu Narayen Elected To Pfizer’s Board Of Directors
NEW YORK, N.Y., September 30 – Pfizer Inc. today announced the election of Shantanu Narayen to its Board of Directors, effective September 27, 2013.  Mr. Narayen also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

Pfizer Consumer Healthcare, a unit of Pfizer, Inc. (NYSE: PFE) and the maker of Advil®, the #1 selling over-the-counter pain reliever in the United States, and the National Hockey League (NHL) today announced Advil® is an Official Partner and the Official Pain Reliever of the NHL® and the 30 NHL athletic trainers in North America

September 24, 2013 - Pfizer Announces Data For XELJANZ® (tofacitinib citrate) In Rheumatoid Arthritis To Be Presented At The American College Of Rheumatology 2013 Annual Meeting

Pfizer Inc. (NYSE: PFE) announced today that 20 abstracts for XELJANZ® (tofacitinib citrate), the first in a new class for the treatment of rheumatoid arthritis (RA), oral Janus kinase (JAK) inhibitors, will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2013 Annual Meeting, which is being held October 25-30 in San Diego, CA.  XELJANZ is approved in the United States for 

September 3, 2013 - Pfizer Invites Public To Listen to Webcast of Pfizer Discussion at Health Care Conference

NEW YORK, N.Y., September 3 -- Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, 

September 3, 2013 - Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease

PRINCETON, N.J. & NEW YORK--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced at the ESC Congress 2013, organized by the European Society of Cardiology, results of a post-hoc subanalysis from the Phase III ARISTOTLE trial, which was designed to demonstrate the efficacy and safety of Eliquiscompared to warfarin for the prevention of stroke or 

August 31, 2013 - New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial. Patients with nonvalvular atrial fibrillation (NVAF) who are anticoagulated to reduce the risk of stroke

August 29, 2013 - Pfizer Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial Of Prevenar 13*

Pfizer announced today the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older. 

July 30, 2013 - Pfizer Reports Second-Quarter 2013 Results
July 25, 2013 - CHMP Confirms Prior Opinion Regarding Marketing Authorization In Europe For Pfizer’s XELJANZ® (tofacitinib citrate)

Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its April 25, 2013, opinion to recommend against approval of XELJANZ® (tofacitinib citrate)


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.